CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.
CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.
复制标题
CCR5 抗体 HGS004 和 HGS101 优先抑制药物结合的 CCR5 感染并恢复原代细胞中马拉维罗耐药 HIV-1 的药物敏感性。
DOI：
10.1016/j.virol.2010.12.029
复制
发表时间：
2011
期刊：
影响因子：
3.7
通讯作者：
Heredia,Alonso
中科院分区：
文献类型：
--
作者：
Latinovic,Olga;Reitz,Marvin;Le,NhutM;Foulke,JamesS;Fatkenheuer,Gerd;Lehmann,Clara;Redfield,RobertR;Heredia,Alonso
R5 HIV-1 strains resistant to the CCR5 antagonist Maraviroc (MVC) can use drug-bound CCR5. We demonstrate that MVC-resistant HIV-1 exhibits delayed kinetics of coreceptor engagement and fusion during drug-bound versus free CCR5 infection of cell lines. Antibodies directed against the second extracellular loop (ECL2) of CCR5 had greater antiviral activity against MVC-bound compared to MVC-free CCR5 infection. However, in PBMCs, only ECL2 CCR5 antibodies HGS004 and HGS101, but not 2D7, inhibited infection by MVC resistant HIV-1 more potently with MVC-bound than with free CCR5. In addition, HGS004 and HGS101, but not 2D7, restored the antiviral activity of MVC against resistant virus in PBMCs. In flow cytometric studies, CCR5 binding by the HGS mAbs, but not by 2D7, was increased when PBMCs were treated with MVC, suggesting MVC increases exposure of the relevant epitope. Thus, HGS004 and HGS101 have antiviral mechanisms distinct from 2D7 and could help overcome MVC resistance.
